Subtleties in GPCR drug discovery: a medicinal chemistry perspective
- PMID: 22732182
- DOI: 10.1016/j.drudis.2012.06.010
Subtleties in GPCR drug discovery: a medicinal chemistry perspective
Abstract
Therapeutic effects through G protein-coupled receptors (GPCRs) are promoted by a full agonist, partial agonist, neutral antagonist or inverse agonist. Dramatic change of function such as from a neutral antagonist to a full agonist with minimal variation of ligand structure is a phenomenon that medicinal chemists often encounter. This is also influenced by a change of assay format. The subtle nature of structure-function relationships is difficult to grasp unless carefully considered from both chemistry and assay perspectives. In this article we discuss the subtle aspects of GPCR drug discovery from the medicinal chemistry perspective.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing?Eur J Pharmacol. 2006 Dec 28;553(1-3):1-9. doi: 10.1016/j.ejphar.2006.09.032. Epub 2006 Sep 26. Eur J Pharmacol. 2006. PMID: 17081515 Review.
-
Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.Med Res Rev. 2014 Nov;34(6):1286-330. doi: 10.1002/med.21318. Epub 2014 May 5. Med Res Rev. 2014. PMID: 24796277 Review.
-
Structure-based drug design for G protein-coupled receptors.Prog Med Chem. 2014;53:1-63. doi: 10.1016/B978-0-444-63380-4.00001-9. Prog Med Chem. 2014. PMID: 24418607 Review.
-
The 7 TM G-protein-coupled receptor target family.ChemMedChem. 2006 Aug;1(8):761-82. doi: 10.1002/cmdc.200600134. ChemMedChem. 2006. PMID: 16902930 Review.
-
Using ligand-induced conformational change to screen for compounds targeting G-protein-coupled receptors.J Biomol Screen. 2007 Mar;12(2):175-85. doi: 10.1177/1087057106298287. Epub 2007 Feb 8. J Biomol Screen. 2007. PMID: 17289935
Cited by
-
Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction.Commun Chem. 2023 Jun 1;6(1):106. doi: 10.1038/s42004-023-00894-6. Commun Chem. 2023. PMID: 37264098 Free PMC article.
-
Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs.Front Mol Biosci. 2022 May 23;9:863099. doi: 10.3389/fmolb.2022.863099. eCollection 2022. Front Mol Biosci. 2022. PMID: 35677880 Free PMC article. Review.
-
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.Pharmacol Rev. 2022 Apr;74(2):340-372. doi: 10.1124/pharmrev.121.000445. Pharmacol Rev. 2022. PMID: 35302044 Free PMC article. Review.
-
Quantitative structural assessment of graded receptor agonism.Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22179-22188. doi: 10.1073/pnas.1909016116. Epub 2019 Oct 14. Proc Natl Acad Sci U S A. 2019. PMID: 31611383 Free PMC article.
-
A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.Nat Commun. 2018 Nov 8;9(1):4687. doi: 10.1038/s41467-018-07133-w. Nat Commun. 2018. PMID: 30409975 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
